https://www.selleckchem.com/pr....oducts/epacadostat-i
To define the characteristics and the outcome of myelitis associated with immune checkpoint inhibitors (ICIs). We performed a retrospective research in the databases of the French Pharmacovigilance Agency and the OncoNeuroTox network for patients who developed myelitis following treatment with ICIs (2011-202. A systematic review of the literature was performed to identify similar cases. We identified 7 patients who developed myelitis after treatment with ICIs (anti-PD1 [n = 6], anti-PD1 + anti-CTLA4 [n = 1]). Neurologic
Like
Comment
Share
